Star Kristina, Choonara Imti
Research Section, Uppsala Monitoring Centre, S-751 40 Uppsala, Sweden.
Academic Division of Child Health, University of Nottingham, Derby, DE22 3DT, UK.
Healthcare (Basel). 2019 Apr 2;7(2):55. doi: 10.3390/healthcare7020055.
Pharmacovigilance, which is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems, generates knowledge to facilitate the rational use of medicines. When a medicine is first marketed, there is limited information on adverse drug reactions (ADRs), especially in paediatrics, where medicines are less likely to have been extensively studied. Knowledge in drug safety is built up over time when more (in number, and more heterogeneous) patients are treated than were studied in the randomised controlled trials preceding the marketing of a medicine. Previously not recognised ADRs are often initially described in case reports and case series. Prospective cohort studies are useful in determining the incidence and risk factors of common ADRs. Case series and pharmacovigilance reporting systems have been useful in identifying previously unknown uncommon ADRs and risk factors for specific ADRs. This brief review provides examples that illustrate how various study designs and data sources contribute to the evolving knowledge of ADRs that is essential to help develop guidelines and improve the rational use of medicines.
药物警戒是一门涉及药物不良反应或任何其他可能的药物相关问题的发现、评估、理解和预防的科学及活动,它所产生的知识有助于促进药物的合理使用。当一种药物首次上市时,关于药物不良反应(ADR)的信息有限,尤其是在儿科,因为在儿科药物不太可能得到广泛研究。随着越来越多(数量更多且更具异质性)的患者接受治疗,与在药物上市前进行的随机对照试验中所研究的患者相比,药物安全性方面的知识会随着时间的推移而积累。以前未被认识到的药物不良反应通常最初在病例报告和病例系列中进行描述。前瞻性队列研究有助于确定常见药物不良反应的发生率和危险因素。病例系列和药物警戒报告系统在识别以前未知的罕见药物不良反应以及特定药物不良反应的危险因素方面发挥了作用。本简要综述提供了一些例子,说明了各种研究设计和数据来源如何为药物不良反应知识的不断发展做出贡献,而这些知识对于制定指南和改善药物的合理使用至关重要。